论文部分内容阅读
目的探讨高血压和动脉粥样硬化患者中基质金属蛋白酶9(MMP9)的水平及临床意义。方法采用ELISA方法对高血压(208例)和动脉粥样硬化(48例)患者、健康对照者(50例)血清MMP9水平进行测定。结果高血压患者、动脉粥样硬化患者、对照组MMP9水平分别为(368.19±48.83)ng/ml、(544.33±50.71)ng/ml、(255.82±25.10)ng/ml,高血压患者血清MMP9水平与动脉粥样硬化患者相比有极显著性差异(P<0.01),且两组与对照组比均有极显著性差异(P<0.01)。结论血清MMP9水平可作为高血压患者向动脉粥样硬化发展的预警指标。
Objective To investigate the levels and clinical significance of matrix metalloproteinase 9 (MMP9) in patients with hypertension and atherosclerosis. Methods Serum levels of MMP9 in patients with hypertension (208 cases), atherosclerosis (48 cases) and healthy controls (50 cases) were determined by ELISA. Results in patients with hypertension, atherosclerosis patients, MMP9 levels in the control group were (368.19 ± 48.83) ng / ml, (544.33 ± 50.71) ng / ml, (255.82 ± 25.10) ng / ml, serum levels in patients with hypertension MMP9 Compared with atherosclerosis patients, there was a significant difference (P <0.01), and the two groups were significantly different from the control group (P <0.01). Conclusion Serum MMP9 level can be used as an early warning index for the development of atherosclerosis in hypertensive patients.